3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
9
Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Pancreatic Neoplasms
6
Colorectal Neoplasms
5
Lymphoma
4
Liver Neoplasms
4
Lung Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Mesothelioma
2
Locally Advanced Rectal Cancer
2
Hematologic Diseases
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Interventions
pembrolizumab
124
Cisplatin
27
lenvatinib
24
Carboplatin
24
Paclitaxel
19
Docetaxel
16
Fluorouracil
13
Capecitabine
11
Pemetrexed
10
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
olaparib
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
spartalizumab
×
Clear all
NCT02403193
2022-01-12
AdenONCO
Palobiofarma SL
Phase 1
Completed
92 enrolled